In conclusion, roflumilast reverses smoke-induced CFTR dysfunction and increases intestinal fluid in mice in a smoke-dependent manner, providing the first in vivo evidence that roflumilast may be functioning as a CFTR activator, which could explain its beneficial effects in COPD patients with bronchitis. This evidence concerns the gene CFTR and chronic obstructive pulmonary disease.